CanSinoBIO's inhalation COVID-19 shot in mid-stage trial, says CEO

1 minute read

A logo of China's vaccine specialist CanSino Biologics Inc is pictured on the company's headquarters in Tianjin, following an outbreak of the coronavirus disease (COVID-19), China August 17, 2020. REUTERS/Thomas Peter/File Photo

Register now for FREE unlimited access to Reuters.com

BEIJING, June 2 (Reuters) - An inhalation version of CanSino Biologics' (6185.HK), COVID-19 vaccine is being tested in a Phase II clinical trial, Chief Executive Yu Xuefeng said late on Wednesday.

Yu made the comment at a panel of the Global Health Forum of the Boao Forum for Asia.

Register now for FREE unlimited access to Reuters.com
Reporting by Roxanne Liu and Ryan Woo Editing by David Goodman

Our Standards: The Thomson Reuters Trust Principles.